By targeting the endothelial cell compartment, bevacizumab not only inhibits the supply of oxygen and nutrients to the tumor, but also interrupts the “paracrine effect” by inhibiting endothelial secretion of growth factors such as IGF1, bFGF, and HB-EGF, which can stimulate tumor proliferation. Here, IGF1 is linked to neoplasm.